SLC7A6OS

Summary

SLC7A6OS (solute carrier family 7 member 6 opposite strand, HGNC:25807) is a protein-coding gene on chromosome 16q22.1, encoding Probable RNA polymerase II nuclear localization protein SLC7A6OS (Q96CW6). Directs RNA polymerase II nuclear import. It is a common-essential gene (DepMap: required in 98.3% of cancer cell lines).

Predicted to be involved in developmental process. Predicted to act upstream of or within hematopoietic progenitor cell differentiation. Predicted to be located in cytoplasm and nucleus. Implicated in progressive myoclonus epilepsy.

Source: NCBI Gene 84138 — RefSeq curated summary.

At a glance

• Gene–disease (curated): epilepsy (Limited, GenCC) — +1 more curated relationship
• GWAS associations: 6
• Clinical variants (ClinVar): 59 total
• Phenotypes (HPO): 13
• Cancer dependency (DepMap): dependent in 98.3% of screened cell lines (common-essential)
• MANE Select transcript: NM_032178

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:25807
Approved symbol	SLC7A6OS
Name	solute carrier family 7 member 6 opposite strand
Location	16q22.1
Locus type	gene with protein product
Status	Approved
Aliases	FLJ13291, Iwr1
Ensembl gene	ENSG00000103061
Ensembl biotype	protein_coding
OMIM	619192
Entrez	84138

Gene structure

Transcript identifiers

Ensembl transcripts: 8 — 6 protein_coding, 1 retained_intron, 1 nonsense_mediated_decay

ENST00000263997, ENST00000561590, ENST00000561933, ENST00000568315, ENST00000568538, ENST00000903598, ENST00000928775, ENST00000928776

RefSeq mRNA: 1 — MANE Select: NM_032178 NM_032178

CCDS: CCDS10865

Canonical transcript exons

ENST00000263997 — 5 exons

Exon	Start	End
ENSE00000844375	68310735	68310946
ENSE00001269453	68298034	68301405
ENSE00003569058	68304026	68304232
ENSE00003659202	68302381	68302501
ENSE00003742032	68310335	68310613

Expression profiles

Bgee: expression breadth ubiquitous, 224 present calls, max score 90.51.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 20.2871 / max 187.6371, expressed in 1817 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
157860	20.2871	1817

Top tissues by expression

240 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
pancreatic ductal cell	CL:0002079	90.51	silver quality
tendon of biceps brachii	UBERON:0008188	88.90	gold quality
apex of heart	UBERON:0002098	88.31	gold quality
endothelial cell	CL:0000115	88.00	gold quality
granulocyte	CL:0000094	87.75	gold quality
gastrocnemius	UBERON:0001388	87.75	gold quality
muscle of leg	UBERON:0001383	87.22	gold quality
tendon	UBERON:0000043	86.36	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	86.34	gold quality
heart left ventricle	UBERON:0002084	85.64	gold quality
tibial nerve	UBERON:0001323	85.60	gold quality
hindlimb stylopod muscle	UBERON:0004252	85.32	gold quality
mucosa of stomach	UBERON:0001199	85.15	gold quality
cardiac ventricle	UBERON:0002082	85.06	gold quality
lymph node	UBERON:0000029	85.02	gold quality
right lobe of thyroid gland	UBERON:0001119	84.87	gold quality
ventricular zone	UBERON:0003053	84.86	gold quality
subcutaneous adipose tissue	UBERON:0002190	84.85	gold quality
leukocyte	CL:0000738	84.83	gold quality
blood	UBERON:0000178	84.74	gold quality
monocyte	CL:0000576	84.70	gold quality
right hemisphere of cerebellum	UBERON:0014890	84.55	gold quality
left lobe of thyroid gland	UBERON:0001120	84.47	gold quality
spleen	UBERON:0002106	84.45	gold quality
lower esophagus muscularis layer	UBERON:0035833	84.38	gold quality
lower esophagus	UBERON:0013473	84.36	gold quality
cerebellar hemisphere	UBERON:0002245	84.19	gold quality
omental fat pad	UBERON:0010414	84.17	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	84.13	gold quality
peritoneum	UBERON:0002358	84.12	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	1.63

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

26 targeting SLC7A6OS, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3667-3P	99.99	67.17	1636
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-1305	99.91	71.43	3443
HSA-MIR-6783-3P	99.89	67.92	2059
HSA-MIR-1343-3P	99.89	66.78	1815
HSA-MIR-6079	99.84	68.54	1170
HSA-MIR-4760-5P	99.80	69.88	1619
HSA-MIR-8061	99.63	69.44	1411
HSA-MIR-18A-3P	99.56	65.68	1092
HSA-MIR-12117	99.50	67.57	868
HSA-MIR-4643	99.49	67.63	1791
HSA-MIR-6828-5P	99.31	69.21	1433
HSA-MIR-4291	99.20	68.88	2969
HSA-MIR-3619-5P	99.00	68.87	2308
HSA-MIR-939-3P	98.97	65.07	2347
HSA-MIR-361-5P	98.95	70.16	1340
HSA-MIR-1304-5P	98.90	68.58	1054
HSA-MIR-374A-3P	98.87	67.82	1531
HSA-MIR-4716-5P	98.82	68.57	1168
HSA-MIR-5006-5P	98.79	66.92	1246
HSA-MIR-214-3P	98.71	68.12	2128
HSA-MIR-761	98.71	68.07	2051
HSA-MIR-6501-3P	98.71	67.45	1480
HSA-MIR-376A-5P	97.70	65.61	863
HSA-MIR-1233-3P	96.81	65.44	573
HSA-MIR-1178-5P	95.83	64.12	504

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 98.3% of screened cell lines, common-essential.

Literature-anchored findings (GeneRIF, showing 2)

• Results describe the characterization of a protease-related protein, ARP1, in Chang-liver cells. (PMID:20510023)
• Progressive Myoclonus Epilepsy Caused by a Homozygous Splicing Variant of SLC7A6OS. (PMID:33085104)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	slc7a6os	ENSDARG00000010596
mus_musculus	Slc7a6os	ENSMUSG00000033106
rattus_norvegicus	Slc7a6os	ENSRNOG00000020049

Protein

Protein identifiers

Probable RNA polymerase II nuclear localization protein SLC7A6OS — Q96CW6 (reviewed: Q96CW6)

Alternative names: ADAMS proteinase-related protein, Solute carrier family 7 member 6 opposite strand transcript

All UniProt accessions (4): Q96CW6, A0A087X0P9, I3L4S1, J3KSD3

UniProt curated annotations — full annotation on UniProt →

Function. Directs RNA polymerase II nuclear import.

Subcellular location. Cytoplasm. Nucleus.

Disease relevance. Epilepsy, progressive myoclonic 12 (EPM12) [MIM:619191] A form of progressive myoclonic epilepsy, a clinically and genetically heterogeneous group of disorders defined by the combination of action and reflex myoclonus, other types of epileptic seizures, and progressive neurodegeneration and neurocognitive impairment. EPM12 is an autosomal recessive form characterized by onset of tonic-clonic seizures and/or myoclonus in the second decade of life. Affected individuals develop cerebellar ataxia associated with progressive cerebral and cerebellar atrophy on brain imaging. Most patients lose ambulation and become wheelchair-bound. Additional more variable features include mild cognitive dysfunction or psychiatric manifestations, such as depression or anxiety. The disease may be caused by variants affecting the gene represented in this entry.

Miscellaneous. When transfected to S.cerevisiae cells, able to partially restore polymerase II mislocalization and cellular shape in IWR1 mutant cells.

Similarity. Belongs to the IWR1/SLC7A6OS family.

RefSeq proteins (1): NP_115554* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR013883	TF_Iwr1_dom	Domain
IPR040218	SLC7A6OS	Family

Pfam: PF08574

UniProt features (14 total): sequence variant 5, compositionally biased region 3, region of interest 2, modified residue 2, chain 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96CW6-F1	66.54	0.07

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (2): 302, 308

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 83 (showing top): GSE45365_NK_CELL_VS_CD8A_DC_UP, GSE45365_NK_CELL_VS_BCELL_UP, GOBP_HEMATOPOIETIC_PROGENITOR_CELL_DIFFERENTIATION, chr16q22, MODULE_207, BRUINS_UVC_RESPONSE_MIDDLE, RATTENBACHER_BOUND_BY_CELF1, VANOEVELEN_MYOGENESIS_SIN3A_TARGETS, GSE14415_INDUCED_VS_NATURAL_TREG_UP, GSE14415_NATURAL_TREG_VS_FOXP3_KO_NATURAL_TREG_DN, CREB3L4_TARGET_GENES, DIDO1_TARGET_GENES, ELF2_TARGET_GENES, FOXN3_TARGET_GENES, ID2_TARGET_GENES

GO Biological Process (3): hematopoietic progenitor cell differentiation (GO:0002244), protein transport (GO:0015031), developmental process (GO:0032502)

GO Molecular Function (0):

GO Cellular Component (2): nucleus (GO:0005634), cytoplasm (GO:0005737)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
hemopoiesis	1
cell differentiation	1
transport	1
intracellular protein localization	1
establishment of protein localization	1
biological_process	1
intracellular membrane-bounded organelle	1
intracellular anatomical structure	1
cellular anatomical structure	1

Protein interactions and networks

STRING

588 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SLC7A6OS	POLR2C	P19387	695
SLC7A6OS	GPN2	Q9H9Y4	667
SLC7A6OS	GPN3	Q9UHW5	662
SLC7A6OS	GPN1	Q9HCN4	641
SLC7A6OS	AXIN1	O15169	638
SLC7A6OS	POLR2B	P30876	604
SLC7A6OS	TNKS2	Q9H2K2	572
SLC7A6OS	TNKS	O95271	570
SLC7A6OS	POLR2E	P19388	564
SLC7A6OS	EAPP	Q56P03	539
SLC7A6OS	RPAP2	Q8IXW5	504
SLC7A6OS	NCDN	Q9UBB6	496
SLC7A6OS	TSSC4	Q9Y5U2	476
SLC7A6OS	POLR2I	P36954	463
SLC7A6OS	BMP4	P12644	447

IntAct

3 interactions, top by confidence:

A	B	Type	Score
AAR2	SNRNP200	psi-mi:“MI:0914”(association)	0.530
Xpo1	IFT56	psi-mi:“MI:0914”(association)	0.350

BioGRID (35): SLC7A6OS (Affinity Capture-MS), SLC7A6OS (Affinity Capture-MS), SLC7A6OS (Affinity Capture-MS), SLC7A6OS (Affinity Capture-MS), SLC7A6OS (Affinity Capture-MS), AAR2 (Affinity Capture-MS), ACAD11 (Affinity Capture-MS), ASPH (Affinity Capture-MS), DHX38 (Affinity Capture-MS), EAPP (Affinity Capture-MS), ECD (Affinity Capture-MS), EFTUD2 (Affinity Capture-MS), EHHADH (Affinity Capture-MS), MTHFD1 (Affinity Capture-MS), OBSL1 (Affinity Capture-MS)

ESM2 similar proteins: A2BDB7, A2CE83, B2ZX90, D3IUT5, E1BXS0, F4IDY7, P0DPK0, P49069, P58501, Q07532, Q0P4A6, Q1JQE2, Q28GJ0, Q28GL6, Q2KJD6, Q2MJV9, Q2TBJ0, Q2WG79, Q2WG80, Q5F3D1, Q5R789, Q5TID7, Q5U3I2, Q5ZHQ6, Q640U0, Q641E3, Q66H73, Q67W65, Q68F53, Q6AYN9, Q6DRL4, Q6NZY4, Q7TPE5, Q7Z2Z1, Q7ZX27, Q80YR7, Q80ZU5, Q86XK3, Q8BQ33, Q8C6C7

Diamond homologs: A2BDB7, Q1JQE2, Q28GL6, Q5U3I2, Q7TPE5, Q96CW6

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

59 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	46
Likely benign	7
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

1881 predictions. Top by Δscore:

Variant	Effect	Δscore
16:68287740:TCCTA:T	acceptor_loss	1.0000
16:68287741:CCTA:C	acceptor_loss	1.0000
16:68287742:CTA:C	acceptor_loss	1.0000
16:68287743:TAGGT:T	acceptor_loss	1.0000
16:68287744:AGGT:A	acceptor_loss	1.0000
16:68287745:G:T	acceptor_loss	1.0000
16:68287870:GG:G	donor_gain	1.0000
16:68287871:GG:G	donor_gain	1.0000
16:68294800:AT:A	donor_gain	1.0000
16:68294802:G:GG	donor_gain	1.0000
16:68296359:CACAG:C	acceptor_loss	1.0000
16:68296360:ACAGT:A	acceptor_gain	1.0000
16:68296361:C:G	acceptor_gain	1.0000
16:68296361:CAGTG:C	acceptor_loss	1.0000
16:68296362:A:AG	acceptor_gain	1.0000
16:68296362:AGT:A	acceptor_gain	1.0000
16:68296363:G:C	acceptor_loss	1.0000
16:68296363:G:GC	acceptor_gain	1.0000
16:68296363:GT:G	acceptor_gain	1.0000
16:68296363:GTG:G	acceptor_gain	1.0000
16:68296363:GTGC:G	acceptor_gain	1.0000
16:68296363:GTGCA:G	acceptor_gain	1.0000
16:68296483:G:GT	donor_gain	1.0000
16:68296510:CAAGG:C	donor_loss	1.0000
16:68296511:AAGGT:A	donor_loss	1.0000
16:68296514:G:T	donor_loss	1.0000
16:68302380:CCT:C	donor_gain	1.0000
16:68302395:T:C	donor_gain	1.0000
16:68304020:CCTTA:C	donor_loss	1.0000
16:68304021:CTTA:C	donor_loss	1.0000

AlphaMissense

2018 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
16:68302448:G:C	N244K	0.993
16:68302448:G:T	N244K	0.993
16:68304103:A:C	Y201D	0.992
16:68302423:A:G	Y253H	0.991
16:68304108:T:A	D199V	0.989
16:68304108:T:G	D199A	0.989
16:68310901:A:T	L9H	0.988
16:68302431:C:G	R250P	0.986
16:68304109:C:G	D199H	0.986
16:68302422:T:C	Y253C	0.983
16:68302432:G:T	R250S	0.982
16:68304107:G:C	D199E	0.981
16:68304107:G:T	D199E	0.981
16:68310889:C:G	R13P	0.981
16:68310891:C:A	K12N	0.981
16:68310891:C:G	K12N	0.981
16:68304109:C:A	D199Y	0.980
16:68304108:T:C	D199G	0.979
16:68310843:T:A	K28N	0.979
16:68310843:T:G	K28N	0.979
16:68302435:A:G	W249R	0.978
16:68302435:A:T	W249R	0.978
16:68302449:T:G	N244T	0.977
16:68302427:A:C	N251K	0.976
16:68302427:A:T	N251K	0.976
16:68302449:T:A	N244I	0.976
16:68304192:A:G	L171S	0.976
16:68310762:G:C	F55L	0.976
16:68310762:G:T	F55L	0.976
16:68310763:A:G	F55S	0.976

dbSNP variants (sampled 300 via entrez): RS1000156517 (16:68303200 G>A), RS1000160210 (16:68311550 C>T), RS1000234417 (16:68309252 G>A), RS1000472065 (16:68302112 G>A), RS1000581059 (16:68307761 C>G,T), RS1000765472 (16:68312768 G>A), RS1001036517 (16:68307297 A>G,T), RS1001114726 (16:68303314 A>G), RS1001182381 (16:68301734 G>A), RS1001224297 (16:68304062 G>C), RS1001233403 (16:68301542 T>C,G), RS1001794883 (16:68312384 C>T), RS1002066084 (16:68306448 A>G), RS1002149395 (16:68308083 G>A), RS1002542708 (16:68306816 C>T)

Disease associations

OMIM: gene MIM:619192 | disease phenotypes: MIM:619191

GenCC curated gene-disease

Disease	Classification	Inheritance
epilepsy	Limited	Autosomal recessive
epilepsy, progressive myoclonic, 12	Limited	Autosomal recessive

Mondo (2): epilepsy, progressive myoclonic, 12 (MONDO:0030936), epilepsy (MONDO:0005027)

Orphanet (0):

HPO phenotypes

13 total (13 of 13 shown, HPO-id order):

HPO	Term
HP:0000007	Autosomal recessive inheritance
HP:0000716	Depression
HP:0000739	Anxiety
HP:0001251	Ataxia
HP:0001260	Dysarthria
HP:0001268	Mental deterioration
HP:0001288	Gait disturbance
HP:0001310	Dysmetria
HP:0001336	Myoclonus
HP:0002069	Bilateral tonic-clonic seizure
HP:0003621	Juvenile onset
HP:0007018	Attention deficit hyperactivity disorder
HP:0011462	Young adult onset

GWAS associations

6 associations (top):

Study	Trait	p-value
GCST002539_84	Schizophrenia	2.000000e-08
GCST006249_87	Serum metabolite levels	6.000000e-11
GCST008906_1	Schizophrenia	3.000000e-06
GCST009597_88	Multiple sclerosis	4.000000e-06
GCST010002_113	Refractive error	2.000000e-14
GCST010083_28	Hemoglobin levels	1.000000e-10

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004509	hemoglobin measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D004827	Epilepsy	C10.228.140.490

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

27 total (human), top 27 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Cyclosporine	increases expression	3
Valproic Acid	affects expression, decreases expression	2
FR900359	affects phosphorylation	1
triphenyl phosphate	affects expression	1
sodium arsenite	increases expression	1
potassium chromate(VI)	affects cotreatment, increases expression	1
epigallocatechin gallate	affects cotreatment, increases expression	1
cylindrospermopsin	increases expression	1
K 7174	increases expression	1
abrine	increases expression	1
Resveratrol	affects cotreatment, increases expression	1
Temozolomide	increases expression	1
Sunitinib	increases expression	1
Acetaminophen	increases expression	1
Air Pollutants	affects expression, increases abundance	1
Caffeine	decreases phosphorylation	1
Copper	affects binding, decreases expression	1
Disulfiram	affects binding, decreases expression	1
Doxorubicin	decreases expression	1
Methyl Methanesulfonate	increases expression	1
Ozone	affects expression, increases abundance	1
Plant Extracts	affects cotreatment, increases expression	1
Quercetin	increases expression	1
Smoke	decreases expression	1
Thiram	increases expression	1
Antirheumatic Agents	increases expression	1
S-Nitrosoglutathione	increases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00004637	PHASE4	COMPLETED	Double-Blind, Placebo-Controlled Trial of Vitamin E as Add-on Therapy for Children With Epilepsy
NCT00043914	PHASE4	COMPLETED	Measurement Of Serum Levels Of Two Antiepileptic Drugs During Conversion In Patients With Epilepsy
NCT00132223	PHASE4	UNKNOWN	Effects on the Diagnostic Accuracy of Magnetic Imaging Angiographies of the Supra-Aortic Vessels by Three Different Magnetic Resonance Contrast Agents in Patients
NCT00133081	PHASE4	UNKNOWN	Study to Improve the Treatment of Epilepsy (SITE)
NCT00137709	PHASE4	UNKNOWN	Hormone Profiles in Adults With Newly Diagnosed Epilepsy
NCT00154076	PHASE4	COMPLETED	A Multicenter Comparative Trial of Zonisamide and Topiramate as Initial Monotherapy in Untreated Epilepsies
NCT00165828	PHASE4	TERMINATED	Efficacy and Safety of an add-on Treatment With Zonisamide in Adults With Focal Epileptic Seizures With or Without Secondary Generalization
NCT00181116	PHASE4	COMPLETED	Levetiracetam for Benign Rolandic Epilepsy
NCT00207935	PHASE4	COMPLETED	Use of Sustained Release Antiepileptic Medication (Depakote® ER) for Pediatric Epilepsy in a Mental Retardation/Developmental Disorder Population
NCT00215592	PHASE4	COMPLETED	Open Label, Zonegran (Zonisamide) In Partial Onset Seizures
NCT00266604	PHASE4	COMPLETED	A Study to Evaluate the Dosing, Effectiveness and Safety of Topiramate for the Treatment of Epilepsy
NCT00288639	PHASE4	COMPLETED	Lyrica (Pregabalin) Administered as an Add-on Therapy for Partial Seizures (LEADER).
NCT00312676	PHASE4	UNKNOWN	Compare Tolerability of an Overnight Switch to Gradual Switch Between Two Different Forms of Depakote
NCT00323947	PHASE4	COMPLETED	Methylphenidate for Treating Attention Deficit Hyperactivity Disorder in Children With Both ADHD and Epilepsy
NCT00385411	PHASE4	COMPLETED	Study of Valproate in Young Patients Suffering From Epilepsy
NCT00522418	PHASE4	TERMINATED	Study Comparing Best Medical Practice With or Without VNS Therapy in Pharmacoresistant Partial Epilepsy Patients
NCT00537940	PHASE4	COMPLETED	Comparative Study Of Pregabalin And Gabapentin As Adjunctive Therapy In Subjects With Partial Seizures
NCT00552526	PHASE4	UNKNOWN	Ketogenic Diet vs.Antiepileptic Drug Treatment in Drug Resistant Epilepsy
NCT00564915	PHASE4	COMPLETED	RCT of the Efficacy of the Ketogenic Diet in the Treatment of Epilepsy
NCT00571155	PHASE4	COMPLETED	Trial of Levetiracetam in Patients With Primary Brain Tumors and Symptomatic Seizures Who Undergo Surgery
NCT00572195	PHASE4	COMPLETED	RNS® System LTT Study
NCT00610532	PHASE4	TERMINATED	Evaluating the Transporter Protein Inhibitor Probenecid In Patients With Epilepsy
NCT00630357	PHASE4	COMPLETED	Trial to Evaluate the Safety and Efficacy of Keppra After Conversion to Mono-therapy in Subjects With Partial Epilepsy
NCT00630630	PHASE4	COMPLETED	Study on Safety and Efficacy of Levetiracetam in the Adjunctive Treatment of Female Subjects With C1 Catamenial Epilepsy
NCT00630968	PHASE4	COMPLETED	S.K.A.T.E.: Safety of Keppra as Adjunctive Therapy in Epilepsy
NCT00631150	PHASE4	COMPLETED	A Phase IV-Pharmacovigilance Study of Keppra Greece - S.K.A.T.E.: Safety of Keppra as Adjunctive Therapy in Epilepsy
NCT00659958	PHASE4	COMPLETED	ZAGAL Study: Evaluating Effectiveness and Tolerability of Zonisamide as Adjunctive Therapy in Patients With Partial Onset Seizures Treated With Two Antiepileptic Drugs
NCT00713622	PHASE4	COMPLETED	Comparing The Effect On Cognition Of Adjunctive Therapy With Zonisamide Versus Sodium Valproate
NCT00807989	PHASE4	COMPLETED	The Efficacy and Safety of Low Dose Combination of LTG and VPA Compared to CBZ Monotherapy
NCT00832884	PHASE4	COMPLETED	The Safety of Intravenous Lacosamide
NCT00869622	PHASE4	COMPLETED	Antiepileptic Drugs and Osteoporotic Prevention Trial
NCT00896987	PHASE4	COMPLETED	Lamotrigine Cognitive Function Study in Adult Untreated Epilepsies
NCT00952081	PHASE4	COMPLETED	A Pilot Study to Evaluate Efficacy and Safety of Clevidipine in Neurosurgical Patients
NCT01118455	PHASE4	TERMINATED	Trial to Assess Vagus Nerve Stimulation Therapy vs. Anti-Epileptic Drug (AED) Treatment in Children With Refractory Seizures
NCT01127165	PHASE4	COMPLETED	Low and High Dose Zonisamide in Children as Monotherapy
NCT01127256	PHASE4	COMPLETED	Comparative Study of Zonisamide and Carbamazepine as an Initial Monotherapy: Efficacy and Safety Evaluation
NCT01140867	PHASE4	COMPLETED	Open-label, Multi-center Trial of Zonisamide as Adjunctive Therapy in Patients With Uncontrolled Partial Epilepsy
NCT01175954	PHASE4	COMPLETED	Cognitive and Behavioral Effects of Lacosamide
NCT01229735	PHASE4	COMPLETED	Levetiracetam Versus Topiramate as Adjunctive Therapy to Evaluate Efficacy and Safety in Subjects With Refractory Partial Onset Seizures
NCT01244724	PHASE4	TERMINATED	Lexapro for Major Depression in Patients With Epilepsy